Alpha Radioisotopes for Cancer

Isotope Supply at Scale

Our Mission

           RadTran is a technology development company focused on closing critical gaps in the procurement of medical isotopes. Our technologies aim to provide a secure supply for emerging diagnostic and therapeutic drug options.

RadTran also investigates and innovates isotope production methods for currently utilized isotopes that may become limited in their future supply or are prohibitively expensive. Current focus is geared towards emerging targeted alpha therapy cancer therapeutics and the particular alpha-emitters in short supply:

Pb-212, Ac-225, Bi-213, Ra-224, Ra-223

IsoCap-AA Technology

RadTran has developed a new approach for the generation of Ra-224 and Ac-225. These isotopes have been identified as the most desirable for TAT applications for both direct use and as prerequisites for two other leading medically-attractive isotopes, Pb-212 and Bi-213. IsoCap-AA, our patent protected technology, enables the efficient extraction of target isotopes from naturally occurring stockpiles of Thorium-232 (Th-232), a natural waste byproduct of mining, at a dramatically lower cost. The stable supply of material produced using our technology will give the pharmaceutical companies the means and confidence for the development of new drugs. Furthermore, it will also provide a scalable supply once the drugs receive commercial approval.

Radioisotopes For Cancer Treatment (TAT)

Targeted Alpha Therapies (TAT) are on the cutting edge of cancer treatment. TAT shows great potential to treat a wide range of cancers with a greatly reduced impact on surrounding healthy tissues. The components required for TAT are targeting mechanisms to seek out cancerous cells and radioactive isotopes to destroy the cancerous cells in the body. Existing supply for the appropriate isotopes is very limited and methods for production are exorbitantly expensive and cannot be scaled to meet the demand as new drugs are developed and approved. This shortage of isotope material is a major roadblock in the research and development of new TAT drugs as pharmaceutical companies wait for a scalable and affordable production technology to become available.

Applications

Announcements

Subscribe for News and Updates

Thank you for subscribing!
Oops! Something went wrong while submitting the form.

Management Team